Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Equity Average (2018 - 2025)

Crinetics Pharmaceuticals has reported Equity Average over the past 8 years, most recently at $1.0 billion for Q4 2025.

  • For Q4 2025, Equity Average fell 4.33% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, down 4.33%, while the annual FY2025 figure was $1.2 billion, 24.3% up from the prior year.
  • Equity Average for Q4 2025 was $1.0 billion at Crinetics Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Over five years, Equity Average peaked at $1.3 billion in Q1 2025 and troughed at $159.2 million in Q1 2021.
  • A 5-year average of $589.8 million and a median of $384.9 million in 2022 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: dropped 22.46% in 2023 and later skyrocketed 219.15% in 2024.
  • Year by year, Equity Average stood at $262.8 million in 2021, then grew by 27.05% to $333.8 million in 2022, then surged by 62.78% to $543.4 million in 2023, then surged by 98.53% to $1.1 billion in 2024, then fell by 4.33% to $1.0 billion in 2025.
  • Business Quant data shows Equity Average for CRNX at $1.0 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.2 billion in Q2 2025.